Sean Ronnekleiv-Kelly, MD, FACS

Assistant Professor

  • Endowed Professor, Ronald E. and Patricia A. Kissinger Surgical Oncology Research Professorship 
  • Division of Surgical Oncology

ronnekleiv-kelly@surgery.wisc.edu

  • Administrative Assistant: (608) 262-2025

600 Highland Avenue
Clinical Science Center
Madison WI 53792-7375

Education

  • MD, University of Colorado School of Medicine
  • General Surgery Residency, University of Wisconsin School of Medicine and Public Health
  • Complex General Surgical Oncology Fellowship, Johns Hopkins Hospital

Clinical Specialties

Certified by the American Board of Surgery in General Surgery and specializes in malignant disease of the pancreas, liver, gallbladder and biliary tree, stomach and small intestine, neuroendocrine tumors and retroperitoneal sarcoma.

Research Interests

Principal research interest is pancreatic cancer. My lab focuses on formation and progression of pancreatic cancer as well as understanding communication within the tumor microenvironment.

Dr. Ronnekleiv-Kelly’s Lab >>

Recent Publications

  • DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
    Ma RK, Tsai PY, Farghli AR, Shumway A, Kanke M, Gordan JD, Gujral TS, Vakili K, Nukaya M, Noetzli L, Ronnekleiv-Kelly S, Broom W, Barrow J, Sethupathy P
    PLoS Genet 2024 Mar 21; 20(3): e1011216
    [PubMed ID: 38512964]

  • Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer.
    Li Z, Mo F, Guo K, Ren S, Wang Y, Chen Y, Schwartz PB, Richmond N, Liu F, Ronnekleiv-Kelly SM, Hu Q
    Med 2024 Apr 12; 5(4): 348-367.e7
    [PubMed ID: 38521069]

  • Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.
    McLean DT, Meudt JJ, Lopez Rivera LD, Schomberg DT, Pavelec DM, Duellman TT, Buehler DG, Schwartz PB, Graham M, Lee LM, Graff KD, Reichert JL, Bon-Durant SS, Konsitzke CM, Ronnekleiv-Kelly SM, Shanmuganayagam D, Rubinstein CD
    Front Oncol 2023; 13: 1253659
    [PubMed ID: 37817770]

  • NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
    Benson AB, D'Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, Borad M, Bowlus C, Brown D, Burgoyne A, Castellanos J, Chahal P, Cloyd J, Covey AM, Glazer ES, Hawkins WG, Iyer R, Jacob R, Jennings L, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Ronnekleiv-Kelly S, Sahai V, Singh G, Stein S, Turk A, Vauthey JN, Venook AP, Yopp A, McMillian N, Schonfeld R, Hochstetler C
    J Natl Compr Canc Netw 2023 Jul; 21(7): 694-704
    [PubMed ID: 37433432]

  • The circadian clock is disrupted in pancreatic cancer.
    Schwartz PB, Nukaya M, Berres ME, Rubinstein CD, Wu G, Hogenesch JB, Bradfield CA, Ronnekleiv-Kelly SM
    PLoS Genet 2023 Jun; 19(6): e1010770
    [PubMed ID: 37262074]

All Publications on PubMed